Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Deloitte
Chinese Patent Office
Argus Health
Medtronic
US Army

Generated: August 24, 2019

DrugPatentWatch Database Preview

Patent: 8,148,067

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,148,067
Title:Methods for diagnosing and monitoring the status of systemic lupus erythematosus
Abstract: The invention presents a method of diagnosing or monitoring the status of systemic lupus erythematosus (SLE) in a subject or patient comprising detecting the expression of all genes of a diagnostic set in the subject or patient wherein the diagnostic set comprises two or more genes having expression correlated with the classification or status of SLE; and diagnosing or monitoring the status of SLE in the subject or patient by applying at least one statistical method to the expression of the genes of the diagnostic set.
Inventor(s): Lal; Preeti G. (Santa Clara, CA), Williams; Gavin E. (Menlo Park, CA), Fry; Kirk E. (Palo Alto, CA), Sun; Jingtao (Foster City, CA), Dedrick; Russell L. (Kensington, CA)
Assignee: Xdx, Inc. (Brisbane, CA)
Application Number:11/938,227
Patent Claims:see list of patent claims

Details for Patent 8,148,067

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Biogen ZINBRYTA daclizumab INJECTABLE;INJECTION 761029 001 2016-05-27 ➤ Sign Up Xdx, Inc. (Brisbane, CA) 2026-11-09 RX search
Biogen Idec TYSABRI natalizumab VIAL; SINGLE-USE 125104 001 2004-11-23 ➤ Sign Up Xdx, Inc. (Brisbane, CA) 2026-11-09 RX search
Abbvie Inc HUMIRA adalimumab VIAL 125057 002 2002-12-31 ➤ Sign Up Xdx, Inc. (Brisbane, CA) 2026-11-09 RX search
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31 ➤ Sign Up Xdx, Inc. (Brisbane, CA) 2026-11-09 RX search
Genzyme LEMTRADA alemtuzumab INJECTABLE;INJECTION 103948 003 2001-05-07 ➤ Sign Up Xdx, Inc. (Brisbane, CA) 2026-11-09 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 002 2001-05-07 ➤ Sign Up Xdx, Inc. (Brisbane, CA) 2026-11-09 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07 ➤ Sign Up Xdx, Inc. (Brisbane, CA) 2026-11-09 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Deloitte
Merck
Farmers Insurance
Daiichi Sankyo
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.